BG-T187 / BeOne Medicines - LARVOL DELTA

BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration (Businesswire) - "Potential drug combinations for development as part of the clinical collaboration will include certain BeOne assets and Revolution Medicines’ four clinical RAS(ON) inhibitors: daraxonrasib, a RAS(ON) multi-selective inhibitor; zoldonrasib, a RAS(ON) G12D-selective inhibitor; elironrasib, a RAS(ON) G12C-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor. Planned combination studies include: BeOne’s MTA-cooperative PRMT5 inhibitor, BGB-58067, and an EGFR x MET x MET trispecific antibody, BG-T187, with either daraxonrasib or zoldonrasib....Under the regional rights agreement, Revolution Medicines has granted BeOne exclusive rights in select Asian markets to develop and commercialize or solely commercialize, depending on the market, these four clinical-stage RAS(ON) inhibitors."

Licensing / partnership • Solid Tumor

Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=153 | Recruiting | Sponsor: BeOne Medicines | N=87 ➔ 153

Enrollment change • First-in-human • Colorectal Cancer • Oncology • Solid Tumor

EGFR x MET tsAb: Differentiated MET biparatopic design with optimal MET inhibitory activity to pursue best-in-class opportunity (AACR 2025) - "Through a comprehensive assessment of EGFR on-target toxicity risk, we demonstrated that BG-T187 show better HEKn selectivity than EGFR/MET bi-specific antibody, indicating potential lower on-target toxicity risk of BG-T187. Collectively, our findings represent a novel EGFR/MET tri-specific antibody with differentiated MET biparatopic and pursue best-in-class potential."

Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • MET

Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=87 | Recruiting | Sponsor: BeiGene | Trial completion date: Jan 2028 ➔ Sep 2028 | Trial primary completion date: Jan 2028 ➔ Sep 2028

Trial completion date • Trial primary completion date • Oncology • Solid Tumor

Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=87 | Recruiting | Sponsor: BeiGene | Active, not recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=87 | Active, not recruiting | Sponsor: BeiGene | Recruiting ➔ Active, not recruiting

Enrollment closed • Oncology • Solid Tumor

Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=87 | Recruiting | Sponsor: BeiGene | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Metastases • Trispecific • Oncology • Solid Tumor

Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=87 | Not yet recruiting | Sponsor: BeiGene

Combination therapy • Metastases • New P1 trial • Trispecific • Oncology • Solid Tumor